help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lukert, B. P.
Right arrow Articles by Stoskopf, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lukert, B. P.
Right arrow Articles by Stoskopf, M. M.

Journal of Clinical Endocrinology & Metabolism, Vol 62, 1056-1058, Copyright © 1986 by Endocrine Society

ARTICLES

Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids

BP Lukert, JC Higgins and MM Stoskopf

Osteocalcin (OC) is a vitamin K-dependent protein which is synthesized by osteoblasts and is present in the circulation. We measured serum OC concentrations in 10 patients receiving corticosteroids (CS) for chronic obstructive pulmonary disease and in 9 hyperthyroid (HT) patients. Mean values ( +/- SE) were as follows: There was a significant correlation between OC and alkaline phosphatase (r = 0.607; P = 0.006) when CS and HT groups were combined. Elevated serum OC concentrations in hyperthyroid patients may reflect increased osteoblastic activity, while decreased levels in corticosteroid-treated patients may reflect decreased osteoblastic activity.


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
C. Kristo, R. Jemtland, T. Ueland, K. Godang, and J. Bollerslev
Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: A prospective, long-term study
Eur. J. Endocrinol., January 1, 2006; 154(1): 109 - 118.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. N. Rosen, A. C. Moses, J. Garber, D. S. Ross, S. L. Lee, L. Ferguson, V. Chen, K. Lee, and S. L. Greenspan
Randomized Trial of Pamidronate in Patients with Thyroid Cancer: Bone Density Is Not Reduced by Suppressive Doses of Thyroxine, But Is Increased by Cyclic Intravenous Pamidronate
J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2324 - 2330.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Roux, P. Oriente, R. Laan, R. A. Hughes, J. Ittner, S. Goemaere, O. Di Munno, J. M. Pouillès, S. Horlait, and B. Cortet
Randomized Trial of Effect of Cyclical Etidronate in the Prevention of Corticosteroid-Induced Bone Loss
J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1128 - 1133.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1986 by The Endocrine Society